Related Experiment Video
Updated: Aug 14, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Association between Gastric Acid Suppression Therapy and Scattered White Spots in the Duodenum: A Retrospective
Mamoru Ito1, Masakuni Kobayashi1, Akira Dobashi1
1Department of EndoscopyThe Jikei University School of MedicineTokyoJapan.
None:
Background and Study Aims Endoscopic duodenal findings remain undescribed after long-term use of antacids despite their known effects on duodenal physiology. We identified scattered white spots (SWSs) as an endoscopic finding of chronic acid suppression in the duodenum and aimed to confirm this association. Patients and Methods In this single-center, two-arm, retrospective study, we reviewed 200 patients who underwent outpatient esophagogastroduodenoscopy: 100 consecutive patients receiving continuous acid-suppression (proton pump inhibitors [PPI] or potassium-competitive acid blockers [P-CAB] ≥ 8 weeks) and 100 consecutive patients with no history of acid-suppression therapy. Two blinded expert endoscopists independently reviewed all white-light endoscopic images of the descending duodenum. SWSs were graded 0 (absent/minimal), 1 (present) or 2 (dense). SWS positive was defined as a combined score ≥2 of the two independent evaluators. Results A total of 648 images from 200 patients (mean age 62 years, 62.5% male) were analyzed. The acid-suppression group included 58 PPI users and 42 P-CAB users. The SWS-positive rates were significantly higher in the acid-suppression group than the non-suppression group (47% vs. 15%; OR 4.33; 95% confidence interval [CI], 2.20-8.50; P < 0.0001). Interobserver agreement was substantial (weighted κ = 0.77; 95% CI, 0.68-0.85). Multivariate logistic regression analysis revealed acid-suppression therapy as an independent factor for SWS (adjusted OR 6.10; 95% CI, 2.89-13.7; P < 0.0001). Conclusions Long-term gastric acid suppression is significantly associated with the presence of duodenal SWS. Duodenal SWS associated with PPIs and P-CABs are under-recognized, and further studies are warranted to determine their clinical significance.
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Gastritis II: Pathophysiology
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
